Intelligent Bio Solutions Inc. (INBS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, INBS scores 29 out of 100 and receives a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each weighted at 20 points:

• Fundamental Cash Engine (7 / 20): Cited alongside ROIC of -35% and an FCF yield of 0%. The score reflects that the business is not currently generating returns on invested capital or free cash flow relative to its market value.
• Whale / 13F Flow (7 / 20): Reflects institutional accumulation and options positioning. The holders section contains no institutional data in the source, so this pillar cannot be traced to specific filings here.
• Insider Conviction (3 / 20): Reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar and indicates weak insider-side signaling in the source data.
• Macro Regime Fit (7 / 20): Reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion.
• Forensic Balance Sheet (5 / 20): Cited alongside an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. The F-Score of 3 out of 9 points to weak financial-health signals across the nine tests.

For a prospective investor, the practical implications are as follows. The upside case rests on a turnaround in operating economics, since current margins and returns are deeply negative. The valuation tradeoff is severe: with a market capitalization of $6.1M against reported net losses in the source, the equity is priced as a speculative option rather than a cash-generating business. Because every fundamental pillar scores at or below 7 of 20, the rating implies that the stock currently lacks offsetting strengths. The analytical takeaway is that this profile is consistent with high forensic risk, and the rating's verdict is to avoid rather than accumulate.

Per the SEC financials, the company reported operating and net losses in each listed period, with free cash flow negative in all three. Gross margin is 40.8%, while operating and net margins are both -60%, and ROIC is -35%. The Altman Z-Score is 2.5, and the Piotroski F-Score is 3 out of 9, per the Roarable RQD rating. Cash declined from $2.2M in FY 2024 to $0.7M in FY 2025, and Debt/Equity is 0.5.

Per the recent news and catalysts section, six items reference INBS, all tagged "MARKET WIRE" with a YELLOW signal light. Headlines cover a TradingView estimates report, a Yahoo Finance seasonal returns chart, a Stock Titan item reporting CEO pay of $661K for fiscal 2026 in an annual report amendment, a Benzinga after-market movers list, a report of INBS slipping 3.83% to $1.76, and a Yahoo Finance seasonal chart for Tenon Medical (TNON). These are largely market-action and aggregator items rather than fundamental catalysts. Risk watch: the CEO compensation disclosure and the reported price decline are the most material items in the feed. The butterfly supply-chain graph lists no supply-chain links and no proprietary signals.

• What specific products and customers generate the reported $3.1M in revenue, and what drives the operating loss?
• How much runway does the reported $0.7M in cash provide against FY 2025 free cash flow of $-9.9M?
• What is the debt balance, given that the source reports debt as N/A while listing Debt/Equity at 0.5?
• Why are EPS and forward valuation metrics unavailable, and what share count underlies the $6.1M market cap?
• What drove the 52-week range from $1.35 to $24.9, and what catalysts underlie the recent price action?